Mattes Glenn R. 4
4 · TFF Pharmaceuticals, Inc. · Filed Dec 29, 2020
Insider Transaction Report
Form 4
Mattes Glenn R.
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2020-12-23$2.50/sh+30,000$75,000→ 40,000 total - Sale
Common Stock
2020-12-23$15.33/sh−30,000$459,900→ 10,000 total - Exercise/Conversion
Stock Options (Right to Buy)
2020-12-23−30,000→ 1,074,227 totalExercise: $2.50From: 2019-05-01Exp: 2028-05-01→ Common Stock (30,000 underlying)
Holdings
- 10,000(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]The transactions reported by this Form 4 were effect pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.
- [F2]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
- [F3]200,000 shares of the option vested and became exercisable on May 1, 2019.